Medgenics raises 29.4m dollars through public offering
Medgenics, the AIM-listed biopharmaceutical company developing treatments for chronic diseases, has closed an underwritten public offering of 5.6m shares of common stock and Series 2013-A warrants to purchase up to an aggregate of 2.8m shares of common stock.
Medgenics, the AIM-listed biopharmaceutical company developing treatments for chronic diseases, has closed an underwritten public offering of 5.6m shares of common stock and Series 2013-A warrants to purchase up to an aggregate of 2.8m shares of common stock.
The shares and the warrants were sold together as a fixed combination, each consisting of one share of common stock and a warrant to purchase one-half of a share of common stock, at a price to the public of $5.25 per fixed combination.
The gross proceeds to Medgenics were $29.4m, before deducting underwriting discounts and commissions and other offering expenses payable by Medgenics.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In addition, Medgenics granted the underwriters a 45-day option to purchase up to an aggregate of 840,000 additional shares of common stock and additional warrants to purchase up to an aggregate of 420,000 shares of common stock.
Medgenics' share price was down 2.90% to 335p at 0800 on Thursday.
MF
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%
Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the US
Medium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.